DEAR DR. ROACH: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.

December 9, 2010 (UPDATED December 10, 2010) (San Antonio, Texas) — The use of aromatase inhibitors for any length of time by postmenopausal women with breast cancer is associated with a significant ...

Table 1 summarizes the confounders encountered and how neuropsychological testing and neurological functional imaging were used to assess the relationships between both chemotherapy and aromatase ...

Dawn L. Hershman, MD, MS, will present work at SABCS 2023 that uses baseline sociodemographic and financial measures to predict which patients prescribed long-term therapy with aromatase inhibitors ...

Precision-calibrated LightGBM machine learning model to predict serious adverse events in oncology patients using FAERS. Effectiveness of the Automated Heart-Health Assessment (AH-HA) tool on ...

Hormone therapy slows hormone-sensitive cancer growth by blocking your body’s ability to make hormones like estrogen and progesterone or blocking the effects of these hormones. But lower levels of ...

With the rapid introduction of novel breast cancer therapies, recognizing and managing side effects is essential to maintain adherence and improve outcomes. As novel oral endocrine therapies and ...

Please provide your email address to receive an email when new articles are posted on . Obesity and severe obesity were linked to increased breast cancer recurrence risk among postmenopausal women.

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy ...

A new research paper was published in Volume 16 of Oncotarget on July 29, 2025, titled "PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast ...

How Do I Take Kisqali? Kisqali is taken as a tablet that you swallow. You take Kisqali once a day for 21 days in a row, and then have 7 days where you do not take Kisqali. This means that in every 28 ...